These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9627860)

  • 21. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceutical registration and how to get a drug on the market.
    Cameron AM; Nimmo WS
    Br J Hosp Med; 1993 Apr 21-May 4; 49(8):583-7. PubMed ID: 8508245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 28. [Safe administration of new drugs].
    Schou J; Pelkonen O; Saano V
    Duodecim; 1996; 112(11):1013-6. PubMed ID: 10592998
    [No Abstract]   [Full Text] [Related]  

  • 29. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

  • 32. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
    Showalter HD; Denny WA
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving drug development: exploratory clinical studies.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):6. PubMed ID: 11366150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Investigation and development of new drugs: from the molecule to drug].
    Marovac J
    Rev Med Chil; 2001 Jan; 129(1):99-106. PubMed ID: 11265215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of how drugs are designed and developed.
    Gallimore D
    Nurs Times; 2006 Nov 21-27; 102(47):30-1. PubMed ID: 17153043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [From the chemical product to the authorization of drug marketing].
    Caulin C
    Rev Prat; 2002 Mar; 52(5):486-90. PubMed ID: 11949499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surviving the blockbuster syndrome.
    Service RF
    Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
    [No Abstract]   [Full Text] [Related]  

  • 40. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.